Meet Patient Needs, Diagnostics Laboratory Launches New Products

Meet Patient Needs, Diagnostics Laboratory Launches New Products

JAKARTA, investor.id – PT Diagnos Laboratorium Utama Tbk (DGNS) launched its latest product, Circle DNA by Diagnos Genomics, a DNA test product that is able to read more than 500 genetic data with a very comprehensive examination.

Managing Director of Main Laboratory Diagnostics Dennis Jacobus explained that the Circle DNA by Diagnos Genomics test is a very comprehensive test that contains 500 reports on nutritional needs, aptitudes, and genetic profiles related to health and response to drugs.

With this examination, he said, patients will get complete information about themselves as a unique individual, and authentic in developing potential, meeting nutritional needs, exercising, and in maintaining health. "Using the examination, patients will get 115 Reports on Risk of Cancer &Disease, 60 Reports on Diet, Fitness, and Health, 163 Reports on carriers of body Gene conditions, 102 Reports on drug sensitivity, 28 Reports on physical and behavioral potential profiles that can be consulted with the Genomics Diagnosis Genetics Counselor," he explained in an official statement, Friday (9/4).

Dennis added that the application of the concept of genetic testing is very important, because in the future each individual will have an individual genomic passport that contains data to show a person's genetic profile. "That way the company can find out the real needs of customers and how to meet optimal needs," he said.

The company said that the company's customers can find information about the Circle DNA by Diagnos Genomics examination through the company's customer service or through the company's official website at www.diagnos.co.id. Meanwhile, until the end of 2020, Diagnos Laboratorium Utama managed to record a positive performance with a net profit growth of 468% to IDR 52 billion, throughout 2020.

Based on investor daily archives, this growth is supported by Biomolecular products in the form of Polymerase Chain Reactions (PCR) examinations. President Director of Diagnostics of the Main Laboratory, Mesha Rizal Sini, explained that this profit growth could be achieved thanks to the Biomolecular product used for Covid-19 disease screening examination, in the form of Polymerase Chain Reactions (PCR) examination. "From April 2020 to December 31, 2020, we have successfully carried out 148,577 PCR tests," he said. Meanwhile, in that period, the net profit recorded by the company came from revenues of IDR 183 billion. This realization increased by 256.8% from the same period in 2019, namely Rp 51.3 billion.

Mesha added, there are several other factors that support growth during 2020, one of which is the addition of new branches and outlets spread across the Denpasar area, Padang. Each of these branches, managed to contribute 6.6% and 0.5% respectively to the company's total annual revenue. Along with the construction of branches, the company also built several outlets located in several strategic cities in Indonesia, namely Diagnos rs Graha Bakti Medika, Diagnos RS Edelweiss, Diagnos Klinik SOS Renon Denpasar, Diagnos Klinik Primecare Panglima Polim, Diagnos BIP Clinic Batam.

Source : https://investor.id/market-and-corporate/penuhi-kebutuhan-pasien-diagnos-laboratorium-luncurkan-produk-baru